Abstract 11P
Background
Adjuvant treatment has become more personalized in resectable NSCLC. New biomarkers are needed to predict treatment outcomes. In this study, we looked for a broadly applicable biomarker using deep learning on hematoxylin and eosin (H&E) histology. Based on recommendations [Salgado et al., Ann Oncol 2015], we focused on analyzing tumor infiltrating lymphocytes in the stromal (sTILs) and the intratumoral (iTILs) compartment. We assessed TILs fully automated at slide and tumor bulk level, guided by manual annotations of the tumor bulk. We hypothesized high iTIL and sTIL density being associated with improved disease-free survival (DFS) in the total study population.
Methods
In this retrospective cohort study, 106 chemo-naive patients with resectable NSCLC were identified in two cohorts, based on recurrence (n=45, cohort A) versus no recurrence (n=61, cohort B). Whole mount tumor slides were stained with H&E and digitalized. Deep learning models were used to compute tissue masks [J. Spronck et al., PLMR 2023] and for TIL detection [HoverNet, Med Imag Anal. 2019]. Tumor bulk was manually annotated to exclude distant tumor lets. Distribution of iTIL and sTIL densities in cohort A and B were compared using Mann-Whitney U based on absence of normal distribution patterns. DFS was measured by log-rank and cox regression to correct for covariates after a binary distinction based on median TIL densities.
Results
The slide and annotation iTIL density were significantly higher in cohort B versus cohort A (slide: 300 vs 232 TILs/mm2, p=0.007 and annotation: 318 vs 230 TILs/mm2, p=0.013). The slide and annotation sTIL density were also higher in cohort B versus A (slide: 1489 vs 1153 TILs/mm2, p=0.035 and annotation: 1753 vs 1469, p=0.030). DFS was significantly higher in patients with a high slide iTIL density compared to patients with a low slide iTIL density (HR 0.44; 95% CI 0.24 to 0.81; P<0.009). DFS remained significant after correction for age, gender, smoking history co-morbidity and clinical stage, but not for ECOG performance.
Conclusions
The iTIL density detected on slide level could serve as favorable prognostic factor in patients with resectable NSCLC, potentially being a biomarker for adjuvant treatment.
Legal entity responsible for the study
The authors.
Funding
NWO/VIDI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract